链脲佐菌素
内科学
酮发生
内分泌学
糖尿病
脂肪肝
医学
脂质代谢
没食子酸
葡萄糖稳态
化学
酮体
新陈代谢
生物化学
抗氧化剂
胰岛素抵抗
疾病
作者
Jung Chao,Hao-Yuan Cheng,Ming-Ling Chang,Shyh-Shyun Huang,Jiunn-Wang Liao,Yung-Chi Cheng,Wen-Huang Peng,Li-Heng Pao
标识
DOI:10.3389/fphar.2020.606759
摘要
Gallic acid (GA) is a simple polyphenol found in food and traditional Chinese medicine. Here, we determined the effects of GA administration in a combined mouse model of high-fat diet (HFD)-induced obesity and low-dose streptozotocin (STZ)-induced hyperglycemia, which mimics the concurrent non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes pathological condition. By combining the results of physiological assessments, pathological examinations, metabolomic studies of blood, urine, liver, and muscle, and measurements of gene expression, we attempted to elucidate the efficacy of GA and the underlying mechanism of action of GA in hyperglycemic and dyslipidemic mice. HFD and STZ induced severe diabetes, NAFLD, and other metabolic disorders in mice. However, the results of liver histopathology and serum biochemical examinations indicated that daily GA treatment alleviated the high blood glucose levels in the mice and decelerated the progression of NAFLD. In addition, our results show that the hepatoprotective effect of GA in diabetic mice occurs in part through a partially preventing disordered metabolic pathway related to glucose, lipids, amino acids, purines, and pyrimidines. Specifically, the mechanism responsible for alleviation of lipid accumulation is related to the upregulation of β -oxidation and ketogenesis. These findings indicate that GA alleviates metabolic diseases through novel mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI